Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $27 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico has reiterated her 'Outperform' rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $27 price target.
August 16, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico has reiterated her 'Outperform' rating on Edgewise Therapeutics and maintained a $27 price target.
The reiteration of the 'Outperform' rating and the maintenance of the $27 price target by Wedbush analyst Laura Chico indicates a positive outlook for Edgewise Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100